GLP-1 Shortage Status: What the FDA Actually Declared and When

"There's a GLP-1 shortage" was true for years and is now a stale headline more often than not. The FDA doesn't leave shortage status to interpretation — it issues formal declaratory orders with specific dates, and those orders are what actually changed the rules for every compounding pharmacy in the country. Here's what the FDA declared, when, and why it still matters even though the shortage itself is behind us.

The two declaratory orders

On December 19, 2024, the FDA issued a declaratory order removing tirzepatide injection products (Mounjaro and Zepbound) from its drug shortage list, based on an analysis that the shortage had been resolved¹. On February 21, 2025, the FDA issued a second declaratory order doing the same for semaglutide injection products (Ozempic and Wegovy)¹. Both orders were formal FDA actions, not informal guidance — they triggered legally binding deadlines for every compounding pharmacy still producing versions of these drugs.

What changed for compounders

A shortage declaration is the legal basis that lets 503A and 503B pharmacies compound a copy of an FDA-approved drug that would otherwise be restricted. Once the FDA declares a shortage resolved, that legal basis disappears on a set timeline. Following the December 2024 order, 503A and 503B pharmacies were required to stop compounding, distributing, and dispensing compounded tirzepatide injection products¹. Following the February 2025 order, 503A pharmacies had to stop compounding semaglutide injection products immediately, and 503B outsourcing facilities were given until May 22, 2025 to wind down¹. Pharmacies that continued compounding beyond these dates were operating outside the law that had permitted the practice in the first place.

The transition wasn't uncontested — a group representing outsourcing facilities challenged both orders in federal court (Outsourcing Facilities Association v. FDA, N.D. Tex.), and the district court denied preliminary injunctions related to both the tirzepatide and semaglutide orders in March and April 2025, allowing the wind-down deadlines to stand¹.

The enforcement wasn't symbolic

State boards of pharmacy treated these orders as binding law, not a suggestion. Nevada's board, for example, notified its licensees that continuing to compound, distribute, or dispense either drug past the effective dates would violate multiple provisions of state pharmacy law and could result in a citation or administrative fine¹. The same letter pointed compounders toward the FDA's separate January 2018 guidance on "essential copies" of commercially available drugs — a narrower carve-out that still allows some compounding in specific circumstances even after a shortage ends, which is part of why "compounded GLP-1" offers didn't disappear entirely once the declaratory orders took effect¹. That carve-out is also why pharmacy transparency matters more now than it did during the shortage years: the automatic, shortage-based justification is gone, so any compounding happening today needs its own specific, checkable rationale.

Why this still matters in 2026

If you're evaluating a program that offers "compounded semaglutide" or "compounded tirzepatide" today, the shortage-based legal justification for that practice is gone as of the dates above. That doesn't mean every compounded offer you see is automatically illegitimate — some compounding continues under other lawful bases, like personalized formulations for a specific patient need that FDA-approved products don't meet — but it does mean "there's a shortage, so this is legal" is no longer an accurate explanation for a compounded GLP-1 offer. A program that's transparent about why it's still compounding, and names a licensed, verifiable pharmacy, is giving you something to check. One that leans on outdated shortage language is worth extra scrutiny — see the full vetting checklist in how to verify a compounding pharmacy is legitimate.

Check the live status yourself

Shortage determinations are dynamic, and the FDA maintains a searchable drug shortage database as the authoritative, current source — it's the tool to check directly rather than relying on any article, including this one, for a real-time answer². If you're weighing a compounded option because you assume brand-name supply is still constrained, verify that assumption first.

"Resolved" describes a legal status, not a promise

One more distinction worth holding onto: an FDA declaratory order resolving a shortage is a determination based on the manufacturer's ability to meet current and projected demand at the time the order issued. It isn't a permanent guarantee against future supply disruption — the FDA can and does redeclare shortages if conditions change. If you're relying on brand-name availability, it's still worth checking the live database rather than assuming a 2024 or 2025 resolution is a fixed, unchangeable fact going forward².

Don't take "essential copies" as blanket cover

Since it's the exception that keeps getting cited, it's worth being skeptical of how it gets used. The guidance is narrow by design — it exists for documented, patient-specific reasons an FDA-approved product can't be used as-is, not as a general license to keep selling a cheaper copy of a drug that's back in full supply. If a program invokes this guidance to justify a compounded offer, ask what the specific, individual clinical reason is for your prescription rather than accepting the guidance's existence as blanket cover for the whole product line.

What this means for your provider decision

With both shortages resolved, the brand-name-vs-compounded decision now rests more on price, insurance coverage, and personal preference than on availability. Compare the current cash-pay landscape on our semaglutide and tirzepatide price boards, and weigh the cost trade-off directly in compounded vs brand-name GLP-1: which actually saves you money.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.